Analysts expect that SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) will announce ($0.43) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have provided estimates for SI-BONE’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.48). SI-BONE posted earnings per share of ($0.37) in the same quarter last year, which would indicate a negative year over year growth rate of 16.2%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, January 1st.
According to Zacks, analysts expect that SI-BONE will report full-year earnings of ($1.77) per share for the current year, with EPS estimates ranging from ($1.85) to ($1.64). For the next financial year, analysts expect that the business will post earnings of ($1.55) per share, with EPS estimates ranging from ($1.63) to ($1.42). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow SI-BONE.
SI-BONE (NASDAQ:SIBN – Get Rating) last issued its quarterly earnings data on Monday, February 28th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The company had revenue of $25.23 million during the quarter. SI-BONE had a negative return on equity of 38.10% and a negative net margin of 62.75%. During the same period in the previous year, the business posted ($0.28) earnings per share.
Shares of SI-BONE stock opened at $21.69 on Wednesday. The stock has a market capitalization of $726.40 million, a P/E ratio of -12.76 and a beta of 1.41. SI-BONE has a 52 week low of $17.96 and a 52 week high of $37.21. The business has a 50 day moving average of $20.84. The company has a current ratio of 10.41, a quick ratio of 9.73 and a debt-to-equity ratio of 0.26.
In other news, Director Jeffrey W. Dunn sold 4,454 shares of the firm’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $20.38, for a total value of $90,772.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura Francis sold 4,777 shares of the firm’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $20.38, for a total value of $97,355.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,546 shares of company stock valued at $296,447. 7.00% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Champlain Investment Partners LLC bought a new stake in SI-BONE during the fourth quarter valued at $43,762,000. Brown Advisory Inc. boosted its stake in SI-BONE by 36.4% during the fourth quarter. Brown Advisory Inc. now owns 3,090,786 shares of the company’s stock valued at $68,646,000 after buying an additional 825,476 shares during the period. American Century Companies Inc. boosted its stake in SI-BONE by 309.1% during the third quarter. American Century Companies Inc. now owns 1,007,009 shares of the company’s stock valued at $21,570,000 after buying an additional 760,836 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in SI-BONE during the fourth quarter valued at $16,445,000. Finally, BlackRock Inc. boosted its stake in SI-BONE by 12.7% during the fourth quarter. BlackRock Inc. now owns 2,699,798 shares of the company’s stock valued at $59,962,000 after buying an additional 304,050 shares during the period.
About SI-BONE (Get Rating)
SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.
- Get a free copy of the StockNews.com research report on SI-BONE (SIBN)
- Constellation Brands Stock is Launching Towards New Highs
- 3 Analyst Favorite Blue-Chip Stocks to Buy Now
- Does PNC Financial Stock Belong in Your Portfolio?
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.